Literature DB >> 28583000

Suicide in primary headaches in 48 countries: A physician-survey based study.

Jose Maria Trejo-Gabriel-Galan1, Irene Aicua-Rapún1, Esther Cubo-Delgado1, Carmen Velasco-Bernal2.   

Abstract

Aim To investigate the relationship between primary headache types and accomplished or attempted suicide in countries from all world regions. Methods Data were obtained using a questionnaire about suicide due to headache in a face-to-face interview with 203 physicians with expertise in headaches. They came from 48 countries, and from all continents. Results Primary headaches cause one suicide per 1,000,000 population each year (1% of the suicide rate due to all causes). Cluster headache and migraines account for 70-80% of them. Suicide attempts are 10 times more frequent than accomplished suicides. Cluster headache poses more risk than migraine. This risk is not often acknowledged, and is increased if there is previous psychiatric history. More than half of the physicians interviewed think it could be reduced with a more aggressive treatment of headaches. Conclusions Cluster headache and migraine are not always benign, and are the cause of the majority of suicides due to headache.

Entities:  

Keywords:  Cephalalgia; epidemiology; migraine; suicidal behavior; cluster headache

Mesh:

Year:  2017        PMID: 28583000     DOI: 10.1177/0333102417714477

Source DB:  PubMed          Journal:  Cephalalgia        ISSN: 0333-1024            Impact factor:   6.292


  3 in total

1.  Anodal frontal tDCS for chronic cluster headache treatment: a proof-of-concept trial targeting the anterior cingulate cortex and searching for nociceptive correlates.

Authors:  Delphine Magis; Kevin D'Ostilio; Marco Lisicki; Chany Lee; Jean Schoenen
Journal:  J Headache Pain       Date:  2018-08-20       Impact factor: 7.277

2.  Understanding the nature of psychiatric comorbidity in migraine: a systematic review focused on interactions and treatment implications.

Authors:  Thomas Dresler; Salvatore Caratozzolo; Kaat Guldolf; Jana-Isabel Huhn; Carmela Loiacono; Triinu Niiberg-Pikksööt; Marta Puma; Giorgia Sforza; Anna Tobia; Raffaele Ornello; Gianluca Serafini
Journal:  J Headache Pain       Date:  2019-05-09       Impact factor: 7.277

3.  Treatment Outcomes in Patients Treated With Galcanezumab vs Placebo: Post Hoc Analyses From a Phase 3 Randomized Study in Patients With Episodic Cluster Headache.

Authors:  David Kudrow; J Scott Andrews; Mallikarjuna Rettiganti; Tina Oakes; Jennifer Bardos; Charly Gaul; Robert Riesenberg; Richard Wenzel; Dulanji Kuruppu; James Martinez
Journal:  Headache       Date:  2020-11-11       Impact factor: 5.887

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.